Application of Quantitative Pharmacology in Development of Therapeutic Monoclonal Antibodies
Journal Title: The AAPS Journal - Year 2010, Vol 12, Issue 4
Abstract
The advancement of therapeutic monoclonal antibodies during various stages of the drug development process can be effectively streamlined when appropriate translational strategies are applied. Design of successful translational strategies for development of monoclonal antibodies should allow for understanding of the dose– and concentration–response relationships with respect to both beneficial and toxic effects from early phases of drug development. Evaluation of relevant biomarkers during early stages of drug development should facilitate the successful design of safe and effective dosing strategies. Moreover, application of quantitative pharmacology is critical for translation of exposure–response relationships early on.
Authors and Affiliations
Mohammad Tabrizi, Cherryl Funelas, Hamza Suria
Keywords
Related Articles
- EP ID EP681408
- DOI 10.1208/s12248-010-9220-2
- Views 68
- Downloads 0
Prodrug Applications for Targeted Cancer Therapy
Prodrugs are widely used in the targeted delivery of cytotoxic compounds to cancer cells. To date, targeted prodrugs for cancer therapy have achieved great diversity in terms of target selection, activation chemistry, as...
Kinetic modeling of plasmid DNA degradation in rat plasma
A major obstacle in gene delivery is the transport of intact plasmid DNA (pDNA) to target sites. We sought to investigate the kinetic processes underlying the degradation of pDNA in a rat plasma model, as this is one of...
Appropriate calibration curve fitting in ligand binding assays
Calibration curves for ligand binding assays are generally characterized by a nonlinear relationship between the mean response and the analyte concentration. Typically, the response exhibits a sigmoidal relationship with...
Screening for Potential Adjuvants Administered by the Pulmonary Route for Tuberculosis Vaccines
Tuberculosis (TB) infects one third of the world’s population, and new infections occur at a rate of 1/s. Better vaccines are needed than the live mycobacterium Bacille Calmette-Guérin (BCG). Alveolar mac...
Erratum to: Is Extrapolation of the Safety and Efficacy Data in One Indication to Another Appropriate for Biosimilars?
The online version of the original article can be found at doi:10.1208/s12248-013-9534-y.